Macupatide + Eloralintide for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This trial is for adults who are overweight or have obesity but do not have type 2 diabetes. Participants should be generally healthy aside from their weight and meet other criteria set by the main study protocol.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive macupatide and/or eloralintide or placebo subcutaneously for weight management
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Eloralintide
- Macupatide
Trial Overview
The study tests two new medications, macupatide and eloralintide, given alone or together, compared to a placebo (inactive treatment), to see how well they help with weight loss over about 64 weeks.
How Is the Trial Designed?
8
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive macupatide SC and eloralintide SC
Participants will receive macupatide SC and eloralintide SC
Participants will receive macupatide SC and eloralintide SC
Participants will receive macupatide subcutaneously (SC)
Participants will receive eloralintide SC
Participants will receive eloralintide SC
Participants will receive eloralintide SC
Participants will receive placebo SC
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.